Delivery of parathyroid hormone for the treatment of osteoporosis

Expert Opinion on Drug Delivery

Volumn 2, Issue 6, 2005, Pages 993-1002

  Morley, Paul ^a  

^a Zelos Therapeutics Inc   (Canada)

Author keywords

Buccal; Inhalation; Nasal; Oral; Osteoporosis; PTH; Pulmonary

Indexed keywords

8 (N 2 HYDROXY 4 METHOXYBENZOYL)AMINOCAPRYLIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BN 003; INSULIN; OCTANOIC ACID DERIVATIVE; OSTABOLIN C; PARATHYROID HORMONE; PARATHYROID HORMONE 131A; PARATHYROID HORMONE DERIVATIVE; PARATHYROID HORMONE RELATED PROTEIN; PARATHYROID HORMONE[1-34]; PLACEBO; RECOMBINANT PARATHYROID HORMONE; UNCLASSIFIED DRUG;

BONE MASS; BONE STRENGTH; CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG INTERMITTENT THERAPY; DRUG PULSE THERAPY; FRAGILITY FRACTURE; HUMAN; HYPERCALCEMIA; LOW DRUG DOSE; NONHUMAN; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; SIDE EFFECT; TRANSDERMAL PATCH;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; HUMANS; OSTEOPOROSIS; PARATHYROID HORMONE; PATIENT COMPLIANCE;

EID: 28244457371     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2.6.993     Document Type: Review

References (67)

1. DOBNIG H, TURNER RT: The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology (1997) 138(11):4607-4612.
2. LOTINUN S, SIBONGA JD, TURNER RT: Differential effects of intermittent and continuous administration of parathyroid hormone on bone histomorphometry and gene expression. Endocrine (2002) 17(1):29-36.
3. MORLEY P, WHITFIELD JF, WILLICK GE: Therapeutic prospects for parathyroid hormone and parathyroid hormone analogs. Curr. Med. Chem. Imm. Endocrinol. Metab. Agents (2001) 1:269-287.
4. HODSMAN AB, FRAHER LJ, WATSON PH: Parathyroid hormone: the clinical experience and prospects. In: Anabolic Treatments for Osteoporosis. JF Whitfield, P Morley (Eds), CRC Press, Boca Raton, FL, US (1998):83-108.
5. CRANDALL C: Parathyroid hormone for treatment of osteoporosis. Arch. Intern. Med. (2002) 162(11):2297-2309.
6. POTTS JT JR, TREGEAR GW, KEUTMANN HT et al.: Synthesis of a biologically active N-terminal tetratriacontapeptide of parathyroid hormone. Proc. Natl Acad. Sci. USA (1971) 68(1):63-67.
7. BRIXEN KT, CHRISTENSEN PM, EJERSTED C, LANGDAHL BL: Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis. Basic Clin. Pharmacol. Toxicol. (2004) 94(6):260-270.
8. SIRIS E: Alendronate in the treatment of osteoporosis: a review of the clinical trials. J. Womens Health Gend. Based Med. (2000) 9(6):599-606.
9. ETTINGER B, BLACK DM, MITLAK BH et al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA (1999) 282(7):637-645.
10. CHESNUT CH 3rd, SILVERMAN S, ANDRIANO K et al.: A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am. J. Med. (2000) 109(4):267-276.
11. RIGGS BL, WAHNER HW, DUNN WL, MAZESS RB, OFFORD KP, MELTON LJ 3rd: Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis. J. Clin. Invest. (1981) 67(2):328-335.
12. NEER RM, ARNAUD CD, ZANCHETTA JR et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. (2001) 344(19):1434-1441.
13. SCHWIETERT HR, GROEN EW, SOLLIE FA, JONKMAN JH: Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1-84)] in healthy postmenopausal volunteers. Clin. Pharmacol. Ther. (1997) 61(3):360-376.
14. HODSMAN AB, HANLEY DA, ETTINGER MP et al.: Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. (2003) 88(11):5212-5220.
15. 2 to stimulate bone growth in ovariectomized rats. J. Bone Miner. Res. (1997) 12(8):1246-1252.
16. MOHAN S, KUTILEK S, ZHANG C et al.: Comparison of bone formation responses to parathyroid hormone (1-34), (1-31), and (2-34) in mice. Bone (2000) 27(4):471-478.
17. 2 and hPTH-(1-34) in healthy humans. J. Clin. Endocrinol. Metab. (1999) 84(8):2739-2743.
18. GOLD DT, SILVERMAN SL: Compliance with osteoporosis medications: challenges for healthcare providers. Medscape Ob/Gyn & Women's Health (2005) 10(1).
19. HODSMAN AB, FRAHER LJ, WATSON PH et al.: A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. (1997) 82(2):620-628.
20. MIKI T, NAKATSUKA K, NAKA H et al.: Effect and safety of intermittent weekly administration of human parathyroid hormone 1-34 in patients with primary osteoporosis evaluated by histomorphometry and microstructural analysis of iliac trabecular bone before and after 1 year of treatment. J. Bone Miner. Metab. (2004) 22(6):569-576.
21. HORWITZ MJ, TEDESCO MB, GUNDBERG C, GARCIA-OCANA A, STEWART AF: Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. (2003) 88(2):569-575.
22. MAHATO RI, NARANG AS, THOMA L, MILLER DD: Emerging trends in oral delivery of peptide and protein drugs. Crit. Rev. Ther. Drug Carrier Syst. (2003) 20(2-3):153-214.
23. WOODLEY JF: Enzymatic barriers for GI peptide and protein delivery. Crit. Rev. Ther. Drug Carrier Syst. (1994) 11(2-3):61-95.
24. GOLDBERG M, GOMEZ-ORELLANA I: Challenges for the oral delivery of macromolecules. Nat. Rev. Drug Discov. (2003) 2(4):289-295.
25. FRIEDMAN DI, AMIDON GL: Oral absorption of peptides: influence of pH and inhibitors on the intestinal hydrolysis of leuenkephalin and analogues. Pharm. Res. (1991) 8(1):93-96.
26. LANGGUTH P, BOHNER V, HEIZMANN J et al.: The challenge of proteolytic enzymes in intestinal peptide delivery. J. Control. Release (1997) 46(1-2):39-57.
27. CHIN CM, GUTIERREZ M, STILL JG, KOSUTIC G: Pharmacokinetics of modified oral calcitonin product in healthy volunteers. Pharmacotherapy (2004) 24(8):994-1001.
28. News Release. Emisphere issues $10 million note to Novartis and enters into option and license agreement (2004).
29. LEONE-BAY A, SATO M, PATON D et al.: Oral delivery of biologically active parathyroid hormone. Pharm. Res. (2001) 18(7):964-970.
30. COLE HW, ROWLEY E, SMITH S et al.: Oral administration of recombinant human PTH (1-34) restores bone mass in osteopenic animals. J. Bone Miner. Res. (1999) 14:S167.
31. SARUBBI D, CAROZZA M, MAYER E, KUTZY T, GENOBLE L: Oral delivery of parathyroid hormone (1-38) in rats and primates. Pharm. Res. (1996) 13:S326.
32. GILLIGAN JP, WAGNER E, FLAZONE LM et al.: Oral delivery of salmon calcitonin in man: results of Phase I clinical studies demonstrating plasma calcitonin levels. J. Bone Miner. Res. (1996) 11:S20.
33. MEHTA N, STERN W, STURMER A, BOLAT A, CHEN J, GILLIGAN J: Oral delivery of PTH analogs by a solid dosage formulation. J. Bone Miner. Res. (2001) 16:S540.
34. FDA news, October 14 (2004).
35. BIRUDARAJ R, MAHALINGAM R, LI X, JASTI BR: Advances in buccal drug delivery. Crit. Rev. Ther. Drug Carrier Syst. (2005) 22(3):295-330.
36. SENEL S, KREMER M, NAGY K, SQUIER C: Delivery of bioactive peptides and proteins across oral (buccal) mucosa. Curr. Pharm. Biotechnol. (2001) 2(2):175-186.
37. CERNEA S, KIDRON M, WOHLGELERNTER J, MODI P, RAZ I: Dose-response relationship of oral insulin spray in healthy subjects. Diabetes Care (2005) 28(6):1353-1357.
38. XU HB, HUANG KX, ZHU YS et al.: Hypoglycaemic effect of a novel insulin buccal formulation in rabbits. Pharmacol. Res. (2002) 46(5):459-467.
39. HOSNY EA, ELKHESHEN SA, SALEH SI: Buccoadhesive tablets for insulin delivery: in-vitro and in-vivo studies. Boll. Chim. Far: (2002) 141(3):210-217.
40. SUZUKI Y, IGA K, YANAI S et al.: Iontophoretic pulsatile transdermal delivery of human parathyroid hormone (1-34). J. Pharm. Pharmacol. (2001) 53(9):1227-1234.
41. SUZUKI Y, NAGASE Y, IGA K et al.: Prevention of bone loss in ovariectomized rats by pulsatile transdermal iontophoretic administration of human PTH(1-34). J. Pharm. Sci. (2002) 91(2):350-361.
42. MEDI BM, SINGH J: Electronically facilitated trasndermal delivery of human parathyroid hormone (1-34). Int. J. Pharm. (2003) 263(1-2):25-33.
43. CHANG S-L, HOFMANN GA, ZHANG L, DEFTOS LJ, BANGA AK: The effect of electroporation on iontophoretic trasndermal delivery of calcium regulating hormones. J. Control. Release (2000) 66(2-3):127-133.
44. GOPALAKRISHNAN V, HWANG S, LOUGHREY H et al.: Administration of ThPTH to humans using Macroflux® transdermal technology results in the rapid delivery of biologically active PTH. J. Bone Miner. Res. (2004) 19(Suppl. 1):S460.
45. JOHNSON PH, QUAY SC: Advances in nasal drug delivery through tight junction technology. Expert Opin. Drug Deliv. (2005) 2(2):281-298.
46. TURKER S, ONUR E, OZER Y: Nasal route and drug delivery systems. Pharm. World Sci. (2004) 26(3):137-142.
47. AGU RU, VALIVETI S, EARLES DC et al.: Intranasal delivery of recombinant human parathyroid hormone [hPTH (1-34)], teriparatide in rats. Endocr. Res. (2004) 30(3):455-467.
48. OHNUMA N: IBC's 2nd International Conference on Osteoporosis: Novel Therapeutic Developments. M Gowen, G Karsenty, GR Mundy D Thompson (Eds), International Business Communications, Southborough, MA, USA (1999).
49. MATSUMOTO T, SHIRAKI M, NAKAMURA T, HAGINO H, IINUMA H: Daily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects. J. Bone Miner. Res. (2004) 19(Suppl. 1):S44.
50. KARAPALIS AC: PTHrP: novel roles in skeletal biology. Curr Pharm Des (2001) 7(8):655-670.
51. CEFALU WT: Concept, strategies, and feasibility of non-invasive insulin delivery. Diabetes Care (2004) 27(1):239-246.
52. OWENS DR, ZINMAN B, BOLLI G: Alternate routes of insulin delivery. Diabet. Med. (2003) 20(11):886-898.
53. CLARK A: Formulation of proteins and peptides for inhalation. dds&s (2002) 2(3):73-77
54. PATTON JS, TRINCHERO P, PLATZ RM: Bioavailability of pulmonary delivered peptides and proteins: α-interferon, calcitonins and parathyroid hormones. J. Control. Release (1994) 28(1-3):79-85.
55. CORKERY K: Inhalable drugs for systemic therapy. Respir. Care (2000) 45(7):831-835.
56. HUSSAIN A, ARNOLD JJ, KHAN MA, AHSAN F: Absorption enhancers in pulmonary protein delivery. J. Control. Release (2004) 94(11):15-24.
57. SCHMEKEL B, BORGSTROM L, WOLLMER P: Difference in pulmonary absorption of inhaled terbutaline in healthy smokers and non-smokers. Thorax (1991) 46(4):225-228.
58. CODRONS V, VANDERBIST F, VERBEECK RK et al.: Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats. J. Pharm. Sci. (2003) 92(5):938-950.
59. WOLFF RK, ALLEN DL, HUGHES BL et al.: The case for route-dependent toxicology comparisons: Using large animal models to speed clinical development of inhaled proteins. Respir. Drug Deliv. (2000) 7:163-170.
60. PATTON JS: Pulmonary delivery of drugs for bone disorders. Adv. Drug Deliv. Rev. (2000) 42(3):239-248.
61. CODRONS V, VANDERBIST F, UCAKAR B, PREAT V, VANBEVER R: Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1-34) from rat lungs. J. Pharm. Sci. (2004) 93(5):1241-1252.
62. PFUTZNER A, FLACKE F, POHL R et al.: Pilot study with technosphere/PTH(1-34) - a new approach for effective pulmonary delivery of parathyroid hormone (1-34). Horm. Metab. Res. (2003) 35(5):319-323.
63. GERBER RA, KOURIDES IA, CAPPELLERI JC et al.: Treatment satisfaction with inhaled insulin in patients with Type I diabetes. Diabetes Care (2001) 24(9):1556-1559.
64. BELMIN J, VALENSI P: Novel drug delivery systems for insulin. clinical potential for use in the elderly. Drugs Aging (2003) 20(4):303-312.
65. STOEVER JA, PALMER JP: Inhaled insulin and insulin antibodies: a new twist to an old debate. Diabetes Technol. Ther. (2002) 4(2):157-161.
66. SHAPIRO DL, LIVINGSTON JN, MANISCALCO WM, FINKELSTEIN JN: Insulin receptors and insulin effects on Type II alveolar epithelial cells. Biochim. Biophys. Acta (1986) 885(2):216-220.
67. HASTINGS RH: Parathyroid hormone-related protein and lung biology. Respir. Physiol. Neurobiol (2004) 142(2-3):95-113.